Patient & Survivor Care
Conference Coverage
Blood Test Shows Promise for Improving CRC Screening
Researchers evaluate new cfDNA blood-based test’s ability to detect CRC.
From the Journals
Is Axillary Surgery in Early Breast Cancer on Its Way Out?
Trial randomizes more than 2,000 patients to receive either axillary lymph node dissection or sentinel-node biopsy only.
Conference Coverage
How New ICI Combos Change Bladder Cancer Management
Immune checkpoint inhibitor combinations have restructured treatment guidelines for metastatic urothelial carcinoma.
Conference Coverage
How Medicare Reimbursement Trends Could Affect Breast Surgeries
A new study showed a decline in Medicare reimbursements for breast cancer surgery by more than 20% from 2003 to 2023.
Conference Coverage
No Routine Cancer Screening Option? New MCED Tests May Help
CanScan, MERCURY, and OncoSeek can detect a range of cancers and recognize the tissue of origin with high accuracy.
Conference Coverage
Ovarian Cancer: Another Promising Target for Liquid Biopsy
A test under development “looks very sensitive for detecting ovarian cancer early.”
From the Journals
Oncologists Voice Ethical Concerns Over AI in Cancer Care
Researchers ask 204 oncologists from 37 states for their views on the ethical implications of using AI for cancer care.
From the Journals
GLP-1 Receptor Agonists Don’t Raise Thyroid Cancer Risk
Researchers compared data from 145,410 patients who initiated GLP-1 RAs and 291,667 patients initiating dipeptidyl peptidase 4 (DPP4) inhibitors...
Feature
What to Know About the Next-Gen FIT for CRC Screening
These multitarget approaches take the standard FIT a step further by testing for additional DNA, RNA, or protein biomarkers associated with CRC to...
Conference Coverage
Circulating Tumor DNA Predicts Early Treatment Response in Patients With HER2-Positive Cancers
New study results suggest ctDNA dynamics provide an early window into predicting response to targeted therapies in patients with HER2-altered...
Conference Coverage
Liquid Biopsy Has Near-Perfect Accuracy for Early Pancreatic Cancer
Researchers develop signature for pancreatic cancer based on microRNAs and cell-free DNA markers in the blood of patients with the disease.